Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 10/20 | 0.77 |
| ▸ | CNR2 | P34972 | 3/20 | 0.58 |
| ▸ | GRM6 | O15303 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 7/20 | 0.46 |
| ▸ | ADORA2B | P29275 | 7/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.46 |
| ▸ | CNR1 | P21554 | 1/20 | 0.45 |
| ▸ | RORB | Q92753 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4086503 | 0.96 | ADORA1 (0.72) | ADORA1CNR2GRM6MAPTMEN1 | |
| SCHEMBL4078131 | 0.93 | ADORA1 (0.68) | ADORA1CNR2GRM6MAPTMEN1 | |
| SCHEMBL3974619 | 0.92 | ADORA1 (0.67) | ADORA1CNR2GRM6MAPTMEN1 | |
| SCHEMBL4076833 | 0.92 | ADORA1 (0.66) | ADORA1CNR2GRM6MAPTMEN1 | |
| SCHEMBL3976892 | 0.91 | ADORA1 (0.68) | ADORA1CNR2GRM6MAPTMEN1 | |
| SCHEMBL4091366 | 0.87 | ADORA1 (1.00) | ADORA1CNR2GRM6MAPTMEN1 | |
| SCHEMBL4080808 | 0.87 | ADORA1 (0.75) | ADORA1CNR2GRM6MAPTMEN1 | |
| SCHEMBL3980249 | 0.82 | GRM6 (0.73) | ADORA1GRM6MAPTMEN1ALDH1A1 | |
| SCHEMBL3980569 | 0.77 | ADORA1 (0.61) | ADORA1CNR2MAPTMEN1ALDH1A1 | |
| SCHEMBL3981712 | 0.76 | GRM6 (0.57) | ADORA1GRM6MAPTMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013049725-A2 | METHODS OF USING ADENOSINE A1 RECEPTOR ACTIVATION FOR TREATING DEPRESSION | TUFTS UNIVERSITY (US) | 2013-04-04 | — | — | WO | claimed |
| US-20140241990-A1 | METHODS OF USING ADENOSINE A1 RECEPTOR ACTIVATION FOR TREATING DEPRESSION | TUFTS UNIVERSITY (US) | 2014-08-28 | — | — | US | disclosed |
| WO-2013049725-A2 | METHODS OF USING ADENOSINE A1 RECEPTOR ACTIVATION FOR TREATING DEPRESSION | TUFTS UNIVERSITY (US) | 2013-04-04 | — | — | WO | disclosed |
| WO-2009049362-A1 | A1 ADENOSINE RECEPTOR ALLOSTERIC ENHANCERS | MONASH UNIVERSITY (AU) | 2009-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140241990-A1 | METHODS OF USING ADENOSINE A1 RECEPTOR ACTIVATION FOR TREATING DEPRESSION | ADORA2A, ADORA1, ADORA3 | ADORA1 2/4885CNR2 66/4885GRM6 138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.